Research Article| Volume 352, ISSUE 1-2, P37-40, May 15, 2015

Download started.


HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients

Published:March 10, 2015DOI:


      Background & objectives

      The role of human leukocyte antigen (HLA) in clinical response to immunotherapy is not completely known. In this study we evaluated the relationship between HLA-DRB1 genotype, which has been proved to be more common in Iranian MS patients, and clinical response to interferon-beta (IFNβ), which is the most common immunotherapy for relapsing–remitting MS.

      Design and setting

      In this study 68 Iranian patients with confirmed diagnosis of RRMS who had been referred to and admitted in Neurology Department of Amiralam and Khatam Hospitals in Tehran were selected. Patients were followed prospectively for 2 years since initiation of therapy and clinical data, including EDSS scores were recorded every 3 months. MRI was performed at the time of diagnosis and each year.


      HLA-DRB1 typing was performed by polymerase chain reaction (PCR) for all patients and data was analyzed by STATA 12th edition.


      There were 47 (69.1%) responders and 21 (30.9%) non-responders. These two groups were demographically and clinically comparable. Fisher's exact test did not show any difference between HLA-DRB1 allele frequencies in responders and non-responders.


      Our findings confirmed the lack of association between HLA-DRB1 and clinical response to IFNβ among MS patients as previous studies had done.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sospedra M.
        • Martin R.
        Immunology of multiple sclerosis.
        Annu Rev Immunol. 2005; 23: 683-747
        • Oksenberg J.R.
        • et al.
        Multiple sclerosis: genomic rewards.
        J Neuroimmunol. 2001; 113: 171-184
        • Kaimen-Maciel D.R.
        • et al.
        HLA-DRB1* allele-associated genetic susceptibility and protection against multiple sclerosis in Brazilian patients.
        Mol Med Rep. 2009; 2: 993-998
        • Villoslada P.
        • et al.
        The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta.
        J Neuroimmunol. 2002; 130: 194-201
        • Goodin D.S.
        • et al.
        Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
        Neurology. 2002; 58: 169-178
        • Durelli L.
        • et al.
        Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?.
        J Neurol Sci. 2000; 178: 37-41
        • Cohen J.A.
        • et al.
        Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders.
        J Neuroimmunol. 1999; 98: 29-36
        • Sormani M.P.
        • De Stefano N.
        Defining and scoring response to IFN-beta in multiple sclerosis.
        Nat Rev Neurol. 2013; 9: 504-512
        • Oksenberg J.R.
        • Barcellos L.F.
        The complex genetic aetiology of multiple sclerosis.
        J Neurovirol. 2000; 6: S10-S14
        • Noseworthy J.H.
        • et al.
        Multiple sclerosis.
        N Engl J Med. 2000; 343: 938-952
        • Abolfazli R.
        • et al.
        Relationship between HLA-DRB1* 11/15 genotype and susceptibility to multiple sclerosis in Iran.
        J Neurol Sci. 2014; 345: 92-96
        • Byun E.
        • et al.
        Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
        Arch Neurol. 2008; 65: 337-344
        • Fusco C.
        • et al.
        HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing–remitting multiple sclerosis.
        Neurology. 2001; 57: 1976-1979
        • Fernandez O.
        • et al.
        HLA class II and response to interferon-beta in multiple sclerosis.
        Acta Neurol Scand. 2005; 112: 391-394
        • Comabella M.
        • et al.
        HLA class I and II alleles and response to treatment with interferon-beta in relapsing–remitting multiple sclerosis.
        J Neuroimmunol. 2009; 210: 116-119
        • Shahbazi M.
        • et al.
        High frequency of the IL-2–330T/HLA-DRB1*1501 haplotype in patients with multiple sclerosis.
        Clin Immunol. 2010; 137: 134-138
        • Chao M.J.
        • et al.
        HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility.
        Proc Natl Acad Sci U S A. 2008; 105: 13069-13074
        • Weinstock-Guttman B.
        • et al.
        Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
        J Neuroimmunol. 2007; 182: 236-239